

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for March 2023

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mantra Pharma Inc.	M-Alendronate	Fosamax	ALENDRONATE SODIUM	70 mg	tablet	02529394
Auro Pharma Inc.	Auro-Emtricitabine-Tenofovir	Truvada	EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE	200 mg & 300 mg	tablet	02490684
Jamp Pharma Corporation	JAMP-Brimonidine	Alphagan	BRIMONIDINE TARTRATE	0.2% w/v	ophthalmic solution	02449226
Jamp Pharma Corporation	Jamp Pyridostigmine Bromide	Mestinon	PYRIDOSTIGMINE BROMIDE	60 mg	tablet	02508362
Mantra Pharma Inc.	M-Fluoxetine	Prozac	FLUOXETINE HCl	20 mg	capsule	02529440
Jamp Pharma Corporation	Jamp Trospium	Trosec	TROSPIUM CHLORIDE	20 mg	tablet	02506661

Mantra Pharma Inc.	M-Sertraline	Zoloft	SERTRALINE HCl	25 mg	capsule	02530937
Mantra Pharma Inc.	M-Sertraline	Zoloft	SERTRALINE HCl	50 mg	capsule	02530945
Mantra Pharma Inc.	M-Sertraline	Zoloft	SERTRALINE HCl	100 mg	capsule	02530953